Cargando…

Bioengineering and computational analysis of programmed cell death ligand-1 monoclonal antibody

The trans-membrane proteins of the B7 family programmed cell death ligand-1 (PD-L1) and programmed death-1 (PD-1) play important roles in inhibiting immune responses and enhancing self-tolerance via T-cell modulation. Several therapeutic antibodies are used to promote T-cell proliferation by prevent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kalim, Muhammad, Ali, Hamid, Rehman, Ashfaq Ur, Lu, Yong, Zhan, Jinbiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633666/ https://www.ncbi.nlm.nih.gov/pubmed/36341340 http://dx.doi.org/10.3389/fimmu.2022.1012499

Ejemplares similares

Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody
por: Liu, Gang, et al.
Publicado: (2021)

Enhancement of interleukin-2 production by bovine peripheral blood mononuclear cells treated with the combination of anti-programmed death-ligand 1 and cytotoxic T lymphocyte antigen 4 chimeric monoclonal antibodies
por: WATARI, Kei, et al.
Publicado: (2021)

Recent Advances in Studying Interfacial Adsorption of Bioengineered Monoclonal Antibodies
por: Hollowell, Peter, et al.
Publicado: (2020)

KIR Genes and Their Ligands Predict the Response to Anti-EGFR Monoclonal Antibodies in Solid Tumors
por: Morales-Estevez, Cristina, et al.
Publicado: (2016)

Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation
por: Fujiwara, Mai, et al.
Publicado: (2017)

Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
por: Shen, Xiangfeng, et al.
Publicado: (2019)

Interplay between programmed death-ligand 1 and non-coding RNAs
por: Ghafouri-Fard, Soudeh, et al.
Publicado: (2022)

Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews
por: Ou, Shun-Long, et al.
Publicado: (2022)

The worthy role of hepatic arterial infusion chemotherapy in combination with anti-programmed cell death protein 1 monoclonal antibody immunotherapy in advanced hepatocellular carcinoma
por: Ding, Yixin, et al.
Publicado: (2023)

IL-1β, But Not Programed Death-1 and Programed Death Ligand Pathway, Is Critical for the Human Th17 Response to Mycobacterium tuberculosis
por: Stephen-Victor, Emmanuel, et al.
Publicado: (2016)

Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy
por: Wang, Yiming, et al.
Publicado: (2018)

Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy
por: Jiang, Yao, et al.
Publicado: (2023)

Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1
por: Tai, Yu-Tzu, et al.
Publicado: (2018)

Bioengineering of Antibody Fragments: Challenges and Opportunities
por: Pirkalkhoran, Sama, et al.
Publicado: (2023)

Causal relationships between gut microbiota and programmed cell death protein 1/programmed cell death-ligand 1: A bidirectional Mendelian randomization study
por: Huang, Yu-Feng, et al.
Publicado: (2023)

Construction of the systemic anticancer immune environment in tumour-bearing humanized mouse by using liposome-encapsulated anti-programmed death ligand 1 antibody-conjugated progesterone
por: Kametani, Yoshie, et al.
Publicado: (2023)

Soluble monomeric human programmed cell death-ligand 1 inhibits the functions of activated T cells
por: Liang, Zhaoduan, et al.
Publicado: (2023)

Advances in the Isolation of Specific Monoclonal Rabbit Antibodies
por: Zhang, Zaibao, et al.
Publicado: (2017)

Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2
por: Xie, Jiajia, et al.
Publicado: (2021)

Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis
por: Xu, Yimin, et al.
Publicado: (2021)

Development and characterization of single domain monoclonal antibody against programmed cell death ligand-1; as a cancer inhibitor candidate
por: Oghalaie, Akbar, et al.
Publicado: (2022)

Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts
por: Goletz, Christoph, et al.
Publicado: (2018)

Tregalizumab – A Monoclonal Antibody to Target Regulatory T Cells
por: König, Martin, et al.
Publicado: (2016)

Characterization of Monoclonal Antibodies Recognizing Citrulline-Modified Residues
por: Chen, Yaqiong, et al.
Publicado: (2022)

Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells
por: Gibbons Johnson, Rachel M., et al.
Publicado: (2017)

Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition
por: Hakroush, Samy, et al.
Publicado: (2021)

Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis
por: Xian, Feng, et al.
Publicado: (2023)

Approaches in Immunotherapy, Regenerative Medicine, and Bioengineering for Type 1 Diabetes
por: Kopan, Christopher, et al.
Publicado: (2018)

The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies
por: Baker, David, et al.
Publicado: (2020)

Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism
por: Jaafar, Jaafar, et al.
Publicado: (2018)

Generation and Characterization of Anti-AA Amyloid-Specific Monoclonal Antibodies
por: Wall, Jonathan S., et al.
Publicado: (2011)

Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success
por: Jaworski, Juan Pablo, et al.
Publicado: (2017)

Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma
por: Aris, Mariana, et al.
Publicado: (2017)

Phage Display Derived Monoclonal Antibodies: From Bench to Bedside
por: Alfaleh, Mohamed A., et al.
Publicado: (2020)

Long-Term Delivery of an Anti-SIV Monoclonal Antibody With AAV
por: Martinez-Navio, José M., et al.
Publicado: (2020)

Monoclonal antibodies targeting the influenza virus N6 neuraminidase
por: Strohmeier, Shirin, et al.
Publicado: (2022)

The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes
por: Ding, Xing-Chen, et al.
Publicado: (2020)

Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by In Situ Silencing of Programmed-Death Ligands
por: Versteven, Maarten, et al.
Publicado: (2022)

Intracellular trafficking of new anticancer therapeutics: antibody–drug conjugates
por: Kalim, Muhammad, et al.
Publicado: (2017)

Tumor-Associated Tertiary Lymphoid Structures: Gene-Expression Profiling and Their Bioengineering
por: Zhu, Genyuan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_a0220ahspqdjsajn0712seh0sn